[go: up one dir, main page]

US2173337A - Preparation having enhanced sexual hormone action and process of making same - Google Patents

Preparation having enhanced sexual hormone action and process of making same Download PDF

Info

Publication number
US2173337A
US2173337A US125122A US12512237A US2173337A US 2173337 A US2173337 A US 2173337A US 125122 A US125122 A US 125122A US 12512237 A US12512237 A US 12512237A US 2173337 A US2173337 A US 2173337A
Authority
US
United States
Prior art keywords
acid
preparation
hormone action
sexual hormone
making same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US125122A
Inventor
Miescher Karl
Wettstein Albert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FIRM OF SOCIETY OF CHEMICAL INDUSTRY IN BASLE
SOC OF CHEMICAL IND
Original Assignee
SOC OF CHEMICAL IND
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SOC OF CHEMICAL IND filed Critical SOC OF CHEMICAL IND
Application granted granted Critical
Publication of US2173337A publication Critical patent/US2173337A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone

Definitions

  • This invention relates to the manufacture of preparations for parenteral use having enhanced sexual hormone action by combining sexual hormones or their derivatives with a compound containing a carboxylic hydroxyl, an alcoholic hydroxyl or a carbonyl group, such as carboxylic acids, monoor dihydric alcohols, ketones or aldehydes. Both saturated compounds and compounds containing double or treble lin'kings have proved efiective.
  • the following table shows the effect of such activators on, for example, the action of the testosterone on young castrated rats (the weight of a rat at the time of castration was to grams; the experiment began 30 days after the castration).
  • the animals received during 10 days daily each a subcutaneous injection of 50 'y of testosterone and the stated quantity of the compound named dissolved in 0.5 cc. of sesame oil. On the 11th day they were examined.
  • oils or other solvents suitable for the parenteral introduction of medicaments or mixtures of such solvents may be used.
  • substituted or unsubstituted carboxylic acids monoor divalent alcohols, ethers, ketones or aldehydes, particularly those of the aliphatic series but also those of .a fatty aromatic nature, may be used alone or in combination with each other.
  • free acids their salts or esters with poly-alcohols or poly-oxy-ketones, these esters containing at least one free hydroxyl group, may be used, for instance the propane diol mono-palmitic acid ester, the glycerol monoor di-palmitic acid ester or the like.
  • the substituted compounds may contain one or more subtives, for example oestrone, oestradiol and their esters as well as with progesterone.
  • the new preparations are useful in therapeutics as sexual hormone preparations.
  • Preparations for parenteral use having enhanced sexual hormone action obtained by combining a sexual hormone selected from the group consisting of testosterone, androstane-diol, androstene-diol, l7-methyl-testosterone, oestrone, oestradiol and androstene-dione with a compound selected from the group consisting of aliphatic carboxylic acids, aliphatic hydroxy-carboxylic acids and aliphatic alcohols.
  • Preparations for parenteral use having enhanced male sexual hormone action obtained by combining testosterone with higher aliphatic
  • Preparations for parenteral use having encarboxylic acids. hanced male sexual hormone action obtained 3.
  • Preparations for parenteral use having enby combining testosterone with higher aliphatic hanced male sexual hormone action obtained alcohols.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Description

Patented Sept. 19, 1939 UNITED STATES PATENT OFFICE HORMONE MAKING SAME Karl Miescher, Riehen,
Basel, Switzerland,
Switzerland No Drawing.
ACTION AND PROCESS OF and Albert Wettstein,
assignors to the firm of S0- ciety of Chemical Industry in Basle, Basel,
Application February 10, 1937, Se-
rial No. 125,122. In Switzerland February 25,
1936 4 Claims.
This invention relates to the manufacture of preparations for parenteral use having enhanced sexual hormone action by combining sexual hormones or their derivatives with a compound containing a carboxylic hydroxyl, an alcoholic hydroxyl or a carbonyl group, such as carboxylic acids, monoor dihydric alcohols, ketones or aldehydes. Both saturated compounds and compounds containing double or treble lin'kings have proved efiective.
The following table shows the effect of such activators on, for example, the action of the testosterone on young castrated rats (the weight of a rat at the time of castration was to grams; the experiment began 30 days after the castration). The animals received during 10 days daily each a subcutaneous injection of 50 'y of testosterone and the stated quantity of the compound named dissolved in 0.5 cc. of sesame oil. On the 11th day they were examined.
Weight in mg. Daily Compounds Formula dose in mg Seminal Prosvesicles tates w-hydroxy-tridecanoic acid. C1:H:t0a 10 132 124 whydror- -margaric acid-.. CHEMOL. 20 184 194 whydroxy-palmitic apid. Guano," 25 150 158 Pyruvic acid (3311403... 10 Q0 Pahnitic acid 0111111103.. 50 260 209 l2-hydroxy-steeric acid. ,CiaHuOaU Ricino'elnidic acid CnHi4O:.. 50 195 207 Stearic acid... CnHaaCa. 50 175 182 Behenolic acid C1zH|aO: 50 160 180 Camphor-Zi-carboxylic acid. CuHmOa-. 25 106 124 l2-ketostearic acid CnHnOz.. 25 125 50 160 186 Elaidic acid 013K140. 10 34 58 5 30 57 50 150 160 25 80 Brassidic acid. CnH4302-- 10 73 93 5 45 66 1 43 53 Bressidic acid without 50 14 38 CaHaOa- 1O 60 8O CnHx:O: 50 12B 178 CaHoOs--. 50 117 158 CiaHMOL- 50 111 129 u-crotonic acid 04111301. 50 90 124 50 85 109 Erucic acid CnHlaOL. 10 47 71 5 44 61 Oleic acid CnHu0a.. 50 60 73 Linoleic acld CuHu0: 50 53 B5 Ethyl alcohol-" C:HuO 50 82 98 Prcpyl alcohol'. 031130-..- 50 117 156 lsopropyl alcohol. CsHsO 50 120 150 Butyl alcohol. C4Hm 50 72 Hexyl alcohol, CoHu0 50 95 125 Octyl alcohol. CBHuO 50 77 Dodecyl alcohol. CnHa 50 95 98 Cetyl aloohol CisHn 50 165 Stearic slcohoL. nHnO... 50 200 220 Olelc alcohol CnHu 50 87 111 Cinnaniic alcohoL. CIHIO 50 80 81 Testosterone alone- 42 66 Sesame oil 14 41 Similar values were attained in combination with androstane diol, androstene-diol, andro stene-dione, methyl-testosterone or the like, as follows for example from the following table:
' With 50 mg. figgg gfi palmitic acid Daily weight in mg. g 'g Compounds dose Seminal Pros- Seminal Prosv tates v tates 17-methylt estosterone 50 58 88 160 210 l7-ethyld1hydrotestos- 500 49 108 70 148 terone 200 19 55 40 60 Androstane 3 cis 17 trans-dial. '200 74 239 308 Androstene-3-trans-l7- 1000 48 71 114 136 trans-diol. 500 30 50 99 120 Androstenedione 500 126 166 208 251 Values obtained with brassidic acid instead of palmitic acid.
Instead of sesame oil other oils or other solvents suitable for the parenteral introduction of medicaments or mixtures of such solvents may be used. Instead of the compounds listed above other substituted or unsubstituted carboxylic acids, monoor divalent alcohols, ethers, ketones or aldehydes, particularly those of the aliphatic series but also those of .a fatty aromatic nature, may be used alone or in combination with each other. Instead of the free acids their salts or esters with poly-alcohols or poly-oxy-ketones, these esters containing at least one free hydroxyl group, may be used, for instance the propane diol mono-palmitic acid ester, the glycerol monoor di-palmitic acid ester or the like. The substituted compounds may contain one or more subtives, for example oestrone, oestradiol and their esters as well as with progesterone.
Instead of the natural sexual hormones artificially made compounds of analogous'action may be similarly used. 1
The new preparations are useful in therapeutics as sexual hormone preparations.
What we claim is:
1. Preparations for parenteral use having enhanced sexual hormone action, obtained by combining a sexual hormone selected from the group consisting of testosterone, androstane-diol, androstene-diol, l7-methyl-testosterone, oestrone, oestradiol and androstene-dione with a compound selected from the group consisting of aliphatic carboxylic acids, aliphatic hydroxy-carboxylic acids and aliphatic alcohols.
2. Preparations for parenteral use having enhanced male sexual hormone action, obtained by combining testosterone with higher aliphatic Preparations for parenteral use having encarboxylic acids. hanced male sexual hormone action, obtained 3. Preparations for parenteral use having enby combining testosterone with higher aliphatic hanced male sexual hormone action, obtained alcohols.
5 by combining testosterone with higher aliphatic KARL MIESCHER.
hydroxy-carboxylic acids. ALBERT WE'ITS'I'EIN.
US125122A 1936-02-25 1937-02-10 Preparation having enhanced sexual hormone action and process of making same Expired - Lifetime US2173337A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH2173337X 1936-02-25

Publications (1)

Publication Number Publication Date
US2173337A true US2173337A (en) 1939-09-19

Family

ID=4567826

Family Applications (1)

Application Number Title Priority Date Filing Date
US125122A Expired - Lifetime US2173337A (en) 1936-02-25 1937-02-10 Preparation having enhanced sexual hormone action and process of making same

Country Status (1)

Country Link
US (1) US2173337A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2831873A (en) * 1954-10-13 1958-04-22 Pfizer & Co C Testosterone 4, 4-dimethyl pentanoate
US2842567A (en) * 1953-05-09 1958-07-08 Boehringer & Soehne Gmbh Therapeutically valuable esters of alcohols and ketoalcohols of the steroid series and process of preparing same
DE973506C (en) * 1953-10-02 1960-03-10 Schering Ag Process for the production of highly concentrated solutions of steroids

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2842567A (en) * 1953-05-09 1958-07-08 Boehringer & Soehne Gmbh Therapeutically valuable esters of alcohols and ketoalcohols of the steroid series and process of preparing same
DE973506C (en) * 1953-10-02 1960-03-10 Schering Ag Process for the production of highly concentrated solutions of steroids
US2831873A (en) * 1954-10-13 1958-04-22 Pfizer & Co C Testosterone 4, 4-dimethyl pentanoate

Similar Documents

Publication Publication Date Title
DE69807454T2 (en) COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYLATED STEROIDS
Overbeek et al. Nor-androstenolonephenylpropionate, a new potent anabolic ester
US2173337A (en) Preparation having enhanced sexual hormone action and process of making same
DE1543273C3 (en) 7 alpha-methyl-delta to the power of 5 (16) -steroids of the oestran series and process for their production
US3637668A (en) N-substituted 4-aminosteroids
DE2548413A1 (en) DEPOT PREPARATIONS IN OIL, UNSATURATED SOLUTION FOR INTRAMUSCULAR INJECTION
US2950291A (en) 17-oxygenated estra-1, 3, 5(10)-triene-1, 4-diols, their esters, and a corresponding quinone
US3242050A (en) 3-enolesters of 1alpha, 2alpha-methylene-3-ketosteroids
US2191576A (en) 3,5,6-trihydroxy androstane and pregnane compounds
Dorfman Biochemistry of the adrenocortical hormones
US3163578A (en) Alkylthiosteroids and methods of their preparation
DE1667958C (en) Persistent oily solutions of therapeutically effective steroid enol ethers
US3721685A (en) Novel 19-nor delta 4,9-pregnadienes
DE1667958B1 (en) Permanent oily solutions of therapeutically effective steuroid enol ethers
DE3511588A1 (en) AQUEOUS CRYSTAL SUSPENSION OF STEROID GLYCOESTERS
DE1493164C3 (en) lbeta-halomethylandrostanes and process for their preparation
Kar et al. The effect of testosterone propionate on total cholesterol content of the testis in young rats
Koch Recent advances in the field of androgens
Hoehn et al. The toxicity of sodium 3, 12‐dihydroxy‐7‐cholanate and its influence on bile flow in rats
US3452061A (en) Steroidal nitrate esters
DE1267218B (en) Process for the production of 19-oxy-delta 4-3-keto-steroids of the androstane or pregnane series
DE1926043C3 (en) New estrogen ethers and methods of making them
DE2047071A1 (en) 11-hydroxylated 1-alpha-2-alpha-methylene steroids - with gestagenic activity
DE1238016B (en) Process for the preparation of S-alkylated or S-acylated 7alpha-mercapto-delta 1,4-3-keto-steroids
US3372173A (en) Seleno-substituted steroid compounds